Welcome to our dedicated page for Baxter Intl SEC filings (Ticker: BAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Baxter International Inc. filings document formal disclosures for a NYSE-listed medtech issuer with common stock and listed global notes. Recent 8-K reports furnish earnings releases, financial-condition updates, dividend declarations, Regulation FD stockholder-engagement materials, executive leadership changes, severance and change-in-control arrangements, and exhibits tied to material corporate actions.
The company’s proxy materials cover board governance, stockholder voting matters, executive compensation and pay-versus-performance disclosures. Debt-related filings describe senior note issuances, supplemental indentures, underwriting arrangements and tender offers, while recurring reports identify registered securities, capital-structure actions and governance controls relevant to Baxter’s medical-device and healthcare-products business.
Grade Joel T. reported acquisition or exercise transactions in this Form 4 filing.
Baxter International executive vice president and CFO Joel T. Grade reported equity awards rather than open-market trades. He received stock options for 103,448 shares at a price of $0.0000 per share and a grant of 42,735 shares of common stock.
The common stock grant represents restricted stock units scheduled to vest in three equal annual installments beginning on March 1, 2027, subject to the vesting conditions in Baxter’s 2021 Incentive Plan. The options become exercisable in three equal annual installments starting on the same date. Following these grants, Grade directly holds 279,828 common shares, including shares in the employee stock plan.
Zielinski Anita A reported acquisition or exercise transactions in this Form 4 filing.
Baxter International senior vice president, chief accounting officer and controller Anita A. Zielinski reported receiving an equity award of 30,864 shares of common stock in the form of restricted stock units at a stated price of $0.00 per share. These units are scheduled to vest in three equal annual installments beginning on March 1, 2027, the first anniversary of the grant date, subject to the vesting conditions in Baxter’s 2021 Incentive Plan. After this award and dividend reinvestments, Zielinski now directly holds 48,214 shares of Baxter common stock.
Baxter International Inc. executive vice president and chief human resources officer Cynthia Carlisle filed an initial statement of beneficial ownership of securities. The Form 3 indicates she held no shares of Baxter common stock directly following the reported date, establishing a baseline for future ownership disclosures.
McDonnell Michael R. reported acquisition or exercise transactions in this Form 4 filing.
Baxter International director Michael R. McDonnell reported receiving a grant of 1,811 shares of Baxter common stock. The shares were granted at a price of $0.0000 per share and are described as fully vested, subject to the applicable grant terms and conditions. Following this award, McDonnell holds 1,811 shares of Baxter common stock directly.
Baxter International Inc. director Michael R. McDonnell filed an initial Form 3 reporting his beneficial ownership. The filing shows he holds no shares of Baxter common stock directly, with total directly owned common shares reported as 0.0000 following the reported position.
Baxter International Inc. describes how it reshaped the company in 2025 through major divestitures and debt reduction. The Kidney Care business was sold to Carlyle for $3.80 billion in cash, yielding about $3.71 billion in pre-tax proceeds and roughly $3.3 billion after tax, which helped repay $3.81 billion of legacy debt. Baxter had $9.48 billion of indebtedness outstanding as of December 31 2025 and is targeting net leverage of about 3.0% by the end of 2026, while maintaining an investment‑grade rating. The company now operates three segments—Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals—after exiting Kidney Care and previously selling its BioPharma Solutions business.
Baxter reports ongoing integration work for the Hillrom acquisition and highlights risks from its higher debt load, supply chain disruptions, global inflation, intense competition, and extensive regulatory oversight. R&D spending was $518 million in 2025 as the company prioritizes connected care and core therapy innovations within a more focused, less diversified portfolio.
Baxter International reported weak fourth-quarter 2025 results, with sales from continuing operations of $2.97 billion, up 8%, but a U.S. GAAP diluted EPS loss from continuing operations of ($2.01) per share. The loss reflects a $485 million goodwill impairment in the Front Line Care unit and a $330 million valuation allowance on U.S. deferred tax assets.
Adjusted diluted EPS from continuing operations was $0.44, down 24% from the prior year, as margins were pressured by unfavorable product mix, non-recurring inventory adjustments, and a higher tax rate. For full-year 2025, sales rose 6% to $11.24 billion, while adjusted diluted EPS from continuing operations increased to $2.27, but total adjusted diluted EPS fell to $2.21 as discontinued operations declined.
The board declared a sharply reduced quarterly cash dividend of $0.01 per share, payable April 1, 2026. For 2026, Baxter guides reported sales growth from continuing operations of flat to 1% and adjusted diluted EPS of $1.85–$2.05, implying softer earnings versus 2025. The company also appointed former Biogen and IQVIA CFO Michael R. McDonnell to its board and announced the resignations of directors Cathy R. Smith and Stephen H. Rusckowski, reducing the board to 10 members.
Baxter International executive Maria Cecilia Soriano reported equity compensation activity. On February 9, 2026, she acquired 2,273 shares of Baxter common stock at $0.00 per share through the vesting of performance share units granted on March 1, 2023.
On the same date, 918 shares were disposed of at $21.73 per share to cover tax withholding triggered by this vesting. After these transactions, she directly beneficially owned 56,006 shares of Baxter common stock, a figure that includes automatic dividend reinvestments.
Baxter International executive David S. Rosenbloom, EVP and General Counsel, reported equity compensation activity. On February 9, 2026, he acquired 17,055 shares of Baxter common stock at $0 from a performance share unit award granted March 1, 2023, which vested after a three-year performance period ending December 31, 2025.
On the same date, 5,225 shares were forfeited at $21.73 to cover taxes from this vesting. After these transactions, he directly owned 119,464 Baxter shares, a figure that includes automatic dividend reinvestments.
Baxter International executive Reazur Rasul reported equity compensation activity. On February 9, 2026, he acquired 18,951 shares of Baxter common stock at $0.00 per share, issued upon vesting of performance share units granted under the company’s 2021 Incentive Plan and 2023 performance share program.
To satisfy tax withholding from this vesting, 5,770 shares were automatically withheld and disposed of at $21.73 per share. After these transactions, Rasul directly owned 139,846 shares of Baxter common stock, which total includes shares from automatic dividend reinvestment.